Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study.
Research article published in Journal of thrombosis and haemostasis : JTH (2024)
Abstract
BACKGROUND: Glanzmann thrombasthenia (GT) is caused by an inherited defect of platelet αIIbβ3 integrin. Concizumab, a monoclonal antibody specific for tissue factor pathway inhibitor, abolishes its anticoagulant effect. OBJECTIVES: To evaluate the in vitro ability of concizumab to improve hemostasis in GT. METHODS: The effects of concizumab were evaluated in whole blood or platelet-rich plasma from GT patients (n = 5-9) using a thrombin generation assay, rotational thromboelastometry (ROTEM), a global fibrinolytic capacity assay, and a flow chamber assay (Total Thrombus formation Analysis System). Washed platelets (WPs) and 20 nM recombinant activated factor VII (rFVIIa) were included for comparison. RESULTS: The lag time in the thrombin generation assay was significantly longer (+85%; P < .0001) in GT patients than in controls. WPs, rFVIIa, and concizumab each significantly improved thrombin generation profiles. The ROTEM clotting time (CT) was significantly longer in GT patients than in controls (677 seconds vs 523 seconds; P = .03). However, CT improved after adding WPs, rFVIIa, or concizumab. Under flow, occlusive thrombi were present in all healthy controls after 10 minutes, whereas platelet-fibrin depositions were not seen in GT patients. Subocclusive or occlusive thrombi formed when GT blood was mixed with WPs, rFVIIa, or concizumab. Clots in GT platelet-rich plasma were more susceptible to fibrinolysis and were improved by WPs, rFVIIa, or concizumab. CONCLUSION: Concizumab enhanced thrombin generation, decreased the ROTEM CT, improved thrombus formation under flow, and reduced clot lysis. Our results demonstrate the potential of concizumab for subcutaneous prophylaxis in GT patients.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Резюме
Glanzmann thrombasthenia (GT) is caused by an inherited defect of platelet αβintegrin. Concizumab, a monoclonal antibody specific for tissue factor pathway inhibitor, abolishes its anticoagulant effect.
Почему это важно для гирудотерапии
В данном исследовании in vitro оценивалось, способен ли концизумаб — моноклональное антитело, нацеленное на ингибитор пути тканевого фактора — улучшить гемостаз в образцах крови пациентов с тромбастенией Гланцманна. Концизумаб усиливал генерацию тромбина, улучшал время свертывания при тромбоэластометрии и улучшал формирование тромба в условиях потока в образцах пациентов с тромбастенией Гланцманна. Данная работа релевантна области ASH лишь в самом широком смысле, поскольку она касается антикоагулянтной/прокоагулянтной модуляции тромбин-связанных путей — той же ферментативной оси, на которую нацелен гирудин. Однако исследование не включает пиявок, гирудина или агентов, полученных из пиявок, что делает его релевантность для гирудотерапии непрямой и ограниченной.
Цитирование
Targeting tissue factor pathway inhibitor with concizumab to improve hemostasis in patients with Glanzmann thrombasthenia: an in vitro study.
Dubut et al. · Journal of thrombosis and haemostasis : JTH, 2024
Связанный клинический контекст
Узнайте, как это исследование связано с клинической практикой
Добавлено в библиотеку ASH: May 28, 2026 · Последнее обновление сайта: June 18, 2026